Low faecal haemoglobin concentration potentially rules out significant colorectal disease
- 30 November 2012
- journal article
- research article
- Published by Wiley in Colorectal Disease
- Vol. 15 (3), e151-e159
- https://doi.org/10.1111/codi.12087
Abstract
Aim The study aimed to determine whether faecal haemoglobin (Hb) concentration can assist in deciding who with lower abdominal symptoms will benefit from endoscopy. Method Faecal Hb concentrations were measured on single samples from 280 patients referred for lower gastrointestinal tract endoscopy from primary care in NHS Tayside who completed a faecal immunochemical test (FIT) for Hb and underwent subsequent endoscopy. Results Among 739 invited patients, FIT and endoscopy were completed by 280 (median age 63 (18–84) years; 59.6% women), with a median time between FIT and endoscopy of 9 days. Six (2.1%) participants had cancer, 23 (8.2%) had high‐risk adenoma (HRA) (more than three adenomas or any > 1 cm), 31 (11.1%) low‐risk adenoma (LRA) and 26 (9.3%) inflammatory bowel disease (IBD) as the most serious diagnosis. Those with cancer had a median faecal Hb of > 1000 ng Hb/ml buffer. Those with cancer + HRA + IBD had a median faecal Hb concentration of 75 ng Hb/ml buffer (95% CI 18–204), which was significantly higher than that of all remaining participants without significant colorectal disease (P < 0.0001). Using a cut‐off faecal Hb concentration of 50 ng Hb/ml buffer, negative predictive values of 100.0%, 94.4%, 93.4% and 93.9% were found for cancer, HRA, LRA and IBD. Patients with reasons for referral other than rectal bleeding and family history did not have high faecal Hb concentrations. Conclusion Faecal Hb concentration measurements have considerable potential to contribute to reducing unnecessary endoscopy for the majority of symptomatic patients.Keywords
This publication has 25 references indexed in Scilit:
- Diagnostic Accuracy of Point-of-Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowel Disease in Primary Care: The Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) StudyClinical Chemistry, 2012
- Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy?Gut, 2012
- Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational studyBMC Gastroenterology, 2012
- Fecal Immunochemical Tests Compared with Guaiac Fecal Occult Blood Tests for Population-Based Colorectal Cancer ScreeningCanadian Journal of Gastroenterology, 2012
- Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programmeJournal of Medical Screening, 2011
- Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million testsGut, 2011
- New faecal tests in gastroenterologyAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2011
- Guidelines for the management of iron deficiency anaemiaGut, 2011
- Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An UpdateThe American Journal of Gastroenterology, 2008
- Faecal occult blood tests – eliminate, enhance or update?Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2008